References
- SipeJDBensonMDBuxbaumJNAmyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of AmyloidosisAmyloid2010173–410110421039326
- MerliniGBellottiVMolecular mechanisms of amyloidosisN Engl J Med2003349658359612904524
- LachmannHJGoodmanHJGilbertsonJANatural history and outcome in systemic AA amyloidosisN Engl J Med2007356232361237117554117
- CaniaABergesioFCurciarelloGThe Florence Register of amyloidosis: 20 years’ experience in the diagnosis and treatment of the disease in the Florence district areaAmyloid201118Suppl 1818321838443
- KoivuniemiRPaimelaLSuomalainenRLeirisalo-RepoMAmyloidosis as a cause of death in patients with rheumatoid arthritisClin Exp Rheumatol200826340841318578961
- GertzMAKyleRASecondary systemic amyloidosis: response and survival in 64 patientsMedicine (Baltimore)19917042462562067409
- SchnitzerTJAnsellBMAmyloidosis in juvenile chronic polyarthritisArthritis Rheum1977202 Suppl245252263902
- MoroniGBanfiGMontoliAChronic dialysis in patients with systemic amyloidosis: the experience in northern ItalyClin Nephrol199238281851516284
- AkpolatTAkpolatIKandemirBBehcet’s disease and AA-type amyloidosisAm J Nephrol2000201687010644872
- SattianayagamPTHawkinsPNGillmoreJDSystemic amyloidosis and the gastrointestinal tractNat Rev Gastroenterol Hepatol200961060861719724253
- TuglularSYalcinkayaFPaydasSA retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in TurkeyNephrol Dial Transplant200217112003200512401861
- BerglundKThysellHKellerCResults, principles and pitfalls in the management of renal AA-amyloidosis; a 10–21 year followup of 16 patients with rheumatic disease treated with alkylating cytostaticsJ Rheumatol19932012205120578014932
- GoldsmithDJRobertsISShortCDMallickNPComplete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndromeNephron19967435725768938683
- HazenbergBPvan RijswijkMHClinical and therapeutic aspects of AA amyloidosisBaillieres Clin Rheumatol1994836616907954868
- MarhaugGThree assays for the characterization and quantitation of human serum amyloid AScand J Immunol19831843293386417768
- HoffmanJSBendittEPChanges in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractionsJ Biol Chem19822571710510105177107614
- ThornCFLuZYWhiteheadASRegulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell linesScand J Immunol200459215215814871291
- UtsunomiyaINagaiSOh-ishiSSequential appearance of IL-1 and IL-6 activities in rat carrageenin-induced pleurisyJ Immunol19911476180318091716281
- RayAShakyaAKumarDBensonMDRayBKInflammation- responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosisJ Immunol200617742601260916888022
- GollaherCJBaussermanLLHepatic catabolism of serum amyloid A during an acute phase response and chronic inflammationProc Soc Exp Biol Med199019432452502113283
- ParmeleeDCTitaniKEricssonLHEriksenNBendittEPWalshKAAmino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoproteinBiochemistry19822114329833037115671
- HusebekkASkogenBHusbyGMarhaugGTransformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivoScand J Immunol19852132832873922050
- TennentGALovatLBPepysMBSerum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosisProc Natl Acad Sci U S A19959210429943037753801
- LiJPGalvisMLGongFIn vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosisProc Natl Acad Sci U S A2005102186473647715843464
- GellermannGPAppelTRTannertARaft lipids as common components of human extracellular amyloid fibrilsProc Natl Acad Sci U S A2005102186297630215851687
- Gershoni-BaruchRBrikRZacksNShinawiMLidarMLivnehAThe contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean feverArthritis Rheum20034841149115512687559
- CazeneuveCAjrapetyanHPapinSIdentification of MEFV-independent modifying genetic factors for familial Mediterranean feverAm J Hum Genet20006751136114311017802
- AltiokOSeguretFTouitouIMEFV sequence variants and amyloidosis: still an enigmatic questionHum Mutat2003211969712497636
- van der HilstJCHRecent insights into the pathogenesis of type AA amyloidosisScientific World Journal20111164165021403980
- SnanoudjRDurrbachAGauthierEChanges in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantationNephrol Dial Transplant20041971779178515150345
- ElkayamOHawkinsPNLachmannHYaronMCaspiDRapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximabArthritis Rheum200246102571257312384913
- LeungNDispenzieriAFervenzaFCRenal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosisAm J Kidney Dis200546227027716112045
- ZeierMPerzJLinkeRPNo regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvementNephrol Dial Transplant200318122644264714605290
- KyleRAWagonerRDHolleyKEPrimary systemic amyloidosis: Resolution of the nephrotic syndrome with melphalan and prednisoneArch Intern Med19821428144514477103624
- GillmoreJDLovatLBPerseyMRPepysMBHawkinsPNAmyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinLancet20013589275242911454373
- LedueTBWeinerDLSipeJDPoulinSECollinsMFRifaiNAnalytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serumAnn Clin Biochem199835Pt 67457539838988
- GillmoreJDHawkinsPNPepysMBAmyloidosis: a review of recent diagnostic and therapeutic developmentsBr J Haematol19979922452569375734
- KeersmaekersTClaesKKuypersDRde VlamKVerschuerenPWesthovensRLong-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritisAnn Rheum Dis200968575976119366896
- Fernandez-NebroAOliveACastroMCVarelaAHRieraEIrigoyenMVLong-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseasesAm J Med2010123545446120399323
- von HuttenHMihatschMLobeckHRudolphBErikssonMRockenCPrevalence and origin of amyloid in kidney biopsiesAm J Surg Pathol20093381198120519561448
- KisilevskyRYoungIDPathogenesis of amyloidosisBaillieres Clin Rheumatol1994836136267954865
- HawkinsPNLavenderJPPepysMBEvaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P componentN Engl J Med199032385085132377176
- PepysMBHerbertJHutchinsonWLTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosisNature2002417688625425912015594
- BodinKEllmerichSKahanMCAntibodies to human serum amyloid P component eliminate visceral amyloid depositsNature20104687320939720962779
- Kluve-BeckermanBHardwickJDuLAntisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosisAmyloid201118313614621830877
- SnowADWillmerJKisilevskyRA close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrilsLab Invest19875766876982447384
- LyonAWNarindrasorasakSYoungIDCo-deposition of basement membrane components during the induction of murine splenic AA amyloidLab Invest19916467857902046330
- StenstadTMagnusJHHusbyGCharacterization of proteoglycans associated with mouse splenic AA amyloidosisBiochem J1994303Pt 26636707980430
- KisilevskyRThe relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000Amyloid200071232510842701
- McCubbinWDKayCMNarindrasorasakSKisilevskyRCircular- dichroism studies on two murine serum amyloid A proteinsBiochem J198825637757833223951
- KisilevskyRLemieuxLJFraserPEKongXHultinPGSzarekWAArresting amyloidosis in vivo using small-molecule anionic sulfonates or sulfates: implications for Alzheimer’s diseaseNat Med1995121431487585011
- GandhiNSManceraRLHeparin/heparan sulfate-based drugsDrug Discov Today20101523–241058106920974281
- ManentiLTansindaPVaglioAEprodisate in amyloid A amyloidosis: a novel therapeutic approach?Expert Opin Pharmacother20089122175218018671471
- DemberLMHawkinsPNHazenbergBPEprodisate for the treatment of renal disease in AA amyloidosisN Engl J Med2007356232349236017554116
- NeurochemNeurochem submits a complete response to FDA approvable letter for Kiacta2006 [cited November 22, 2011]. Available from: http://drugs.com/nda/kiacta_061016.html
- CT Development America, IncEfficacy and safety study of KIACTA in preventing renal function decline in AA amyloidosisClinicalTrials gov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated December 6, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01215747?term=eprodisate&rank=1. NLM identifier:NCT01215747Accessed February 7, 2012